I have not heard back from you. My question was not to simply repeat what had already been conveyed to you previously by a colleague.
So here is the general information:
aimovig is a treatment for the prevention of migraines in people who have not had the expected effects or acceptable tolerance with other agents. It is given as a subcutaneous injection once a month. In studies, it has been shown to decrease the number of days with a migraine by about 6 days (placebo did this at about 4 days).
It is usually well tolerated, the main side effect being a reaction (redness, pain) at the injection site.
One dose (so 1 month) costs about 500$, plus pharmaceutical fees and related costs, and the product is not covered by the RAMQ
Given this astronomical price and the fact that a multitude of options exist for prevention, this is why the product should be kept as a 3rd or 4th choice, for now.
I hope I have been of some help to you and remain available if you have any further questions!
Tom Samaha, pharmacist